Antihypertensive Therapy Guidelines

First-Line Antihypertensive Medications

The American Heart Association recommends thiazide-like diuretics, ACE inhibitors, ARBs, and calcium channel blockers as first-line agents for initial antihypertensive therapy, with specific choices based on patient characteristics and comorbidities 1
Thiazide-like diuretics are preferred due to their proven efficacy in reducing cardiovascular events, as supported by the American Diabetes Association 1, 2
ARBs provide similar benefits to ACE inhibitors with fewer side effects, making them valuable in patients who cannot tolerate ACE inhibitors, according to the American Diabetes Association 2, 3
Dihydropyridine calcium channel blockers are effective first-line agents, especially in older patients and Black patients, as recommended by the American Heart Association 1, 2

For patients with diabetes and albuminuria, the American Diabetes Association recommends an ACE inhibitor or ARB as first-line treatment to reduce the risk of progressive kidney disease 3, 4
For patients with established coronary artery disease, ACE inhibitors or ARBs are recommended as first-line therapy by the American Heart Association 2, 5
For Black patients, calcium channel blockers and thiazide diuretics are generally more effective than ACE inhibitors, as suggested by the American Heart Association 1
For patients ≥60 years old, calcium channel blockers or thiazide diuretics are often preferred, according to the American Geriatrics Society 6

For patients with blood pressure ≥150/90 mmHg, initial therapy with two antihypertensive medications is recommended by the American Heart Association 2, 3
Preferred combinations include ACE inhibitor or ARB + calcium channel blocker, and ACE inhibitor or ARB + thiazide-like diuretic, as recommended by the American Diabetes Association 2, 6
Combinations to avoid include ACE inhibitor + ARB, which increases the risk of hyperkalemia without additional benefit, as warned by the American Heart Association 2, 5

The American Diabetes Association recommends monitoring serum creatinine and potassium within 7-14 days after initiating ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists, and at least annually thereafter 3, 4
The American Heart Association advises watching for hyperkalemia when using ACE inhibitors or ARBs, especially in combination with mineralocorticoid receptor antagonists 2
ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, direct renin inhibitors, and neprilysin inhibitors are contraindicated in pregnancy and should be avoided in women of childbearing potential who are not using reliable contraception, as recommended by the American College of Obstetricians and Gynecologists 3

Underdosing medications before adding additional agents is a common pitfall, as noted by the American Geriatrics Society 6
Failing to consider ethnicity in medication selection is another pitfall, as ACE inhibitors and ARBs are less effective in Black patients, according to the American Heart Association 1
Using ACE inhibitor + ARB combinations increases adverse effects without additional benefit, as warned by the American Diabetes Association 2
Overlooking the need for more aggressive initial therapy in patients with markedly elevated blood pressure is a pitfall, as recommended by the American Heart Association 2, 3

For stage 2 hypertension, the American College of Cardiology recommends initiating combination therapy with two antihypertensive agents from different classes, with a dihydropyridine calcium channel blocker plus an ACE inhibitor or ARB, when blood pressure is ≥160/100 mmHg or more than 20/10 mmHg above target 7, 8
Prompt blood pressure reduction reduces cardiovascular risk in this high-risk population, with monthly evaluation and prompt adjustment required until control is achieved 7

The European Society of Cardiology recommends the combination of a dihydropyridine calcium channel blocker with an ACE inhibitor or ARB as a guideline-recommended preferred combination for stage 2 hypertension, offering superior cardiovascular outcomes and complementary mechanisms 9
The ACCOMPLISH trial demonstrated that ACE-I + calcium antagonist reduced CV events by 21% compared to ACE-I + diuretic, despite only a 1 mmHg difference in blood pressure control 9

The American Heart Association suggests that either an ACE inhibitor or ARB can be used with a DHP-CCB, with ARBs offering similar efficacy but fewer side effects, particularly cough 7

The American Academy of Family Physicians recommends the combination of ACE-I or ARB + thiazide-like diuretic as an alternative preferred combination, which is also highly effective, with thiazide diuretics remaining cost-effective and proven to reduce cardiovascular events 8, 7

The American College of Cardiology recommends starting with standard combination doses and titrating monthly until blood pressure <130/80 mmHg is achieved, with evidence-based combinations including amlodipine + ACE inhibitor 7

The European Society of Cardiology advises against combining an ACE inhibitor with an ARB, as this increases risk of hyperkalemia, hypotension, and renal dysfunction without additional cardiovascular benefit 9

The American Heart Association recommends monitoring serum creatinine and potassium within 7-14 days after initiating ACE-I or ARB therapy, then at least annually, with monthly blood pressure assessment until control achieved (<130/80 mmHg) 7

The American College of Cardiology recommends a treatment goal of <130/80 mmHg for all patients with stage 2 hypertension, regardless of age, with this lower target supported by SPRINT and meta-analyses showing continued cardiovascular benefit at progressively lower blood pressure levels 7